Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire) - Jul 27, 2023 - "Plus Therapeutics, Inc...today announced that the Company will share three poster presentations at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California. The presentations will describe new data from the ReSPECT-LM and ReSPECT-GBM clinical studies evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases (LM) and recurrent glioblastoma (rGBM), respectively, as well as details around the planned ReSPECT-PBC trial to evaluate rhenium (186Re) obisbemeda for the treatment of recurrent, refractory, or progressive childhood ependymoma and high-grade glioma (HGG)."
P1 data • P1/2 data • Brain Cancer • CNS Tumor • Ependymoma • Glioblastoma • Glioma • Oncology • Solid Tumor
|